Medpace Holdings Inc

MEDP: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$311.00FcvqlmPxcpdgcn

Medpace Earnings: Cancellations Cause Near-Term Headwinds; Positive Long-Term Outlook

Medpace reported mixed second-quarter results, as revenue increased 14.6% from the prior-year period but net new business awards decreased 4% due to elevated cancellations, which were double the quarterly average of 4.5% in 2023. This resulted in a book-to-bill ratio of 1.04 in the second quarter compared with 1.2 in the first quarter of 2024. However, management raised its 2024 earnings per share guidance by 4% at the midpoint, which signals confidence in its profitability and industry-leading organic revenue growth.

Sponsor Center